Barrett H. Childs
About
Barrett H. Childs is a scholar working on Oncology, Pathology and Forensic Medicine and Pulmonary and Respiratory Medicine.
According to data from OpenAlex, Barrett H. Childs has authored 101 papers receiving a total of 3.3k indexed citations (citations by other indexed papers that have themselves been cited), including 53 papers in Oncology, 44 papers in Pathology and Forensic Medicine and 41 papers in Pulmonary and Respiratory Medicine. Recurrent topics in Barrett H. Childs's work include Lymphoma Diagnosis and Treatment (38 papers), Chronic Lymphocytic Leukemia Research (29 papers) and Lung Cancer Treatments and Mutations (19 papers). Barrett H. Childs is often cited by papers focused on Lymphoma Diagnosis and Treatment (38 papers), Chronic Lymphocytic Leukemia Research (29 papers) and Lung Cancer Treatments and Mutations (19 papers). Barrett H. Childs collaborates with scholars based in United States, Germany and Italy. Barrett H. Childs's co-authors include Mark D. Pegram, Sumanta K. Pal, Hugo Castro‐Malaspina, Farid Boulad, Nancy A. Kernan, Esperanza B. Papadopoulos, James W. Young, Alfred P. Gillio, Matthew Carabasi and Stephen Mackinnon and has published in prestigious journals such as New England Journal of Medicine, Journal of Clinical Oncology and Blood.
In The Last Decade
Barrett H. Childs
96 papers receiving 3.2k citations
Hit Papers
Peers — A (Enhanced Table)
Peers by citation overlap · career bar shows stage (early→late) cites · hero ref
| Name | h | Career | Trend | Papers | Cites | |||||
|---|---|---|---|---|---|---|---|---|---|---|
| Barrett H. Childs United States | 20 | 2.1k | 731 | 585 | 572 | 567 | 101 | 3.3k | ||
| Byron M. Espina United States | 29 | 1.6k 0.8× | 959 1.3× | 1.0k 1.8× | 455 0.8× | 370 0.7× | 73 | 3.5k | ||
| Ming‐Tseh Lin United States | 30 | 1.2k 0.6× | 614 0.8× | 853 1.5× | 897 1.6× | 736 1.3× | 76 | 3.3k | ||
| Martin Gutierrez United States | 36 | 2.3k 1.1× | 1.1k 1.6× | 772 1.3× | 1.7k 3.0× | 484 0.9× | 205 | 4.5k | ||
| J Garcı́a-Conde Spain | 35 | 2.0k 1.0× | 1.1k 1.5× | 425 0.7× | 954 1.7× | 584 1.0× | 104 | 3.9k | ||
| John Gutheil United States | 17 | 2.3k 1.1× | 635 0.9× | 820 1.4× | 1.1k 2.0× | 457 0.8× | 40 | 4.2k | ||
| Morten Mau‐Sørensen Denmark | 28 | 1.2k 0.6× | 310 0.4× | 527 0.9× | 1.1k 1.9× | 541 1.0× | 130 | 2.7k | ||
| Daniel E. Stepan United States | 17 | 1.3k 0.6× | 260 0.4× | 627 1.1× | 538 0.9× | 303 0.5× | 35 | 2.8k | ||
| Dimitriοs Mavroudis Greece | 34 | 2.0k 0.9× | 198 0.3× | 612 1.0× | 935 1.6× | 845 1.5× | 179 | 3.9k | ||
| Patricia Pautier France | 33 | 1.8k 0.9× | 568 0.8× | 902 1.5× | 1.6k 2.8× | 600 1.1× | 200 | 4.8k | ||
| Martin Gutierrez United States | 15 | 3.0k 1.4× | 1.2k 1.7× | 500 0.9× | 646 1.1× | 315 0.6× | 44 | 4.0k |
Countries citing papers authored by Barrett H. Childs
Since
Specialization
Citations
This map shows the geographic impact of Barrett H. Childs's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Barrett H. Childs with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Barrett H. Childs more than expected).
Fields of papers citing papers by Barrett H. Childs
Since
Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences
This network shows the impact of papers produced by Barrett H. Childs. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Barrett H. Childs. The network helps show where Barrett H. Childs may publish in the future.
Co-authorship network of co-authors of Barrett H. Childs
This figure shows the co-authorship network connecting the top 25 collaborators of Barrett H. Childs. A scholar is included among the top collaborators of Barrett H. Childs based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Barrett H. Childs. Barrett H. Childs is excluded from the visualization to improve readability, since they are connected to all nodes in the network.
All Works
1.
Chaturvedi, Shalini, Tine Descamps, David R. Bauer, et al.. (2025). Exploratory biomarker analysis from a phase III study of the PI3K inhibitor, copanlisib, in combination with rituximab in patients with indolent non-Hodgkin lymphoma, a retrospective study. Clinical & Translational Oncology. 27(8). 3439–3448.
2.
Carneiro, Benedito A., Robert M. Jotte, Nashat Gabrail, et al.. (2025). Safety and Efficacy of Copanlisib in Combination with Nivolumab: A Phase Ib Study in Patients with Advanced Solid Tumors. Cancer Research Communications. 5(3). 444–457.
3.
Morcos, Peter N., Rolf Burghaus, Jonathan Moss, et al.. (2023). Model‐informed approach to support pediatric dosing for the pan‐PI3K inhibitor copanlisib in children and adolescents with relapsed/refractory solid tumors. Clinical and Translational Science. 16(7). 1197–1209.
4.
Santin, Alessandro D., Ignace Vergote, Antonio González-Martı́n, et al.. (2022). Safety and activity of anti-mesothelin antibody–drug conjugate anetumab ravtansine in combination with pegylated-liposomal doxorubicin in platinum-resistant ovarian cancer: multicenter, phase Ib dose escalation and expansion study. International Journal of Gynecological Cancer. 33(4). 1–9.
5.
Matasar, Matthew J., Martin Dreyling, Sirpa Leppä, et al.. (2021). Feasibility of Combining the Phosphatidylinositol 3-Kinase Inhibitor Copanlisib With Rituximab-Based Immunochemotherapy in Patients With Relapsed Indolent B-cell Lymphoma. Clinical Lymphoma Myeloma & Leukemia. 21(11). e886–e894.
6.
Tan, Daniel S.W., Jay Patel, Ulrik Lassen, et al.. (2021). MA11.09 Efficacy and Safety of Larotrectinib in Patients with Tropomyosin Receptor Kinase (TRK) Fusion Lung Cancer. Journal of Thoracic Oncology. 16(3). S176–S176.
7.
Kummar, Shivaani, Cornelis M. van Tilburg, Catherine M. Albert, et al.. (2020). Quality of life of adults and children with TRK fusion cancer treated with larotrectinib compared to the general population.. Journal of Clinical Oncology. 38(15_suppl). 3614–3614.
8.
Hong, David S., Shivaani Kummar, Anna F. Farago, et al.. (2019). Larotrectinib efficacy and safety in adult TRK fusion cancer patients.. Journal of Clinical Oncology. 37(15_suppl). 3122–3122.
9.
Tilburg, Cornelis M. van, Steven G. DuBois, Catherine M. Albert, et al.. (2019). Larotrectinib efficacy and safety in pediatric TRK fusion cancer patients.. Journal of Clinical Oncology. 37(15_suppl). 10010–10010.
10.
Dreyling, Martin, Panayiotis Panayiotidis, Miklós Egyed, et al.. (2017). Efficacy of Copanlisib Monotherapy in Patients with Relapsed or Refractory Marginal Zone Lymphoma: Subset Analysis from the CHRONOS-1 Trial. Blood. 130. 4053–4053.
11.
Hassan, Raffit, Ross Jennens, Jan P. van Meerbeeck, et al.. (2017). P2.06-027 Randomized Phase II Study of Anetumab Ravtansine or Vinorelbine in Patients with Metastatic Pleural Mesothelioma. Journal of Thoracic Oncology. 12(1). S1087–S1088.
12.
Dreyling, Martin, Armando Santoro, Sirpa Leppä, et al.. (2017). Copanlisib in patients with relapsed or refractory follicular lymphoma.. Journal of Clinical Oncology. 35(15_suppl). 7535–7535.
13.
Hassan, Raffit, John Nemunaitis, Jan P. van Meerbeeck, et al.. (2016). Abstract CT083: A pivotal randomized phase II study of anetumab ravtansine or vinorelbine in patients with advanced or metastatic pleural mesothelioma after progression on platinum/pemetrexed-based chemotherapy (NCT02610140). Cancer Research. 76(14_Supplement). CT083–CT083.
14.
Höchster, Howard S., Axel Grothey, L. Hart, et al.. (2014). Improved time to treatment failure with an intermittent oxaliplatin strategy: results of CONcePT. Annals of Oncology. 25(6). 1172–1178.
15.
Dreyling, Martin, David Cunningham, Krimo Bouabdallah, et al.. (2014). Phase 2A Study of Copanlisib, a Novel PI3K Inhibitor, in Patients with Indolent Lymphoma. Blood. 124(21). 1701–1701.
16.
Sparano, Joseph A., Lori J. Goldstein, Barrett H. Childs, et al.. (2011). Relationship between Quantitative GRB7 RNA Expression and Recurrence after Adjuvant Anthracycline Chemotherapy in Triple-Negative Breast Cancer. Clinical Cancer Research. 17(22). 7194–7203.
17.
Pal, Sumanta K., Barrett H. Childs, & Mark D. Pegram. (2010). Triple negative breast cancer: unmet medical needs. Breast Cancer Research and Treatment. 125(3). 627–636.
18.
Martín, Miguel, John R. Mackey, Tadeusz Pieńkowski, et al.. (2010). Abstract S4-3: Ten-Year Follow-Up Analysis of the BICRG 001 Trial Confirms Superior DFS and OS Benefit of Adjuvant TAC (Docetaxel, Doxorubicin, Cyclophosphamide) over FAC (fluorouracil, Doxorubicin, Cyclophosphamide) in Women with Operable Node-Positive Breast Cancer. Cancer Research. 70(24_Supplement). S4–3.
19.
Sparano, Joseph A., Lori J. Goldstein, Barrett H. Childs, et al.. (2009). Relationship between Topoisomerase 2A RNA Expression and Recurrence after Adjuvant Chemotherapy for Breast Cancer. Clinical Cancer Research. 15(24). 7693–7700.
20.
Pal, Sumanta K., Barrett H. Childs, & Mark D. Pegram. (2009). Emergence of nonanthracycline regimens in the adjuvant treatment of breast cancer. Breast Cancer Research and Treatment. 119(1). 25–32.
Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.
Explore authors with similar magnitude of impact
Breakdown of academic impact, for papers by Byron M. Espina Breakdown of academic impact, for papers by Ming‐Tseh Lin Breakdown of academic impact, for papers by Martin Gutierrez Breakdown of academic impact, for papers by J Garcı́a-Conde Breakdown of academic impact, for papers by John Gutheil Breakdown of academic impact, for papers by Morten Mau‐Sørensen Breakdown of academic impact, for papers by Daniel E. Stepan Breakdown of academic impact, for papers by Dimitriοs Mavroudis Breakdown of academic impact, for papers by Patricia Pautier Breakdown of academic impact, for papers by Martin Gutierrez